Clay Siegall Believe in the Power of Collaboration to Improve Cancer Treatment Options

Inspirey published the interview, “Dr. Clay Siegall—CEO, Seattle Genetics” to show the inspiration of the targeted cancer therapy hero. Dr. Siegall is the co-founder, President, and CEO of Seattle Genetics. Seattle Genetics is a biotech company that creates targeted cancer therapy drugs that use antibodies and cell-killing agents to target tumors. The drugs are particularly focused in treating Hodgkin lymphoma and relapsed systemic anaplastic lymphoma.

He believes a powerful aspect of the business is through collaboration with other industry leaders, particularly oncology drug development companies. Through the collaboration, Seattle Genetics’ technology allows them to become more innovative with new approaches to help other patients.

Through the strong leadership of Dr. Clay Siegall, Seattle Genetics has grown into one of the leaders in the cancer research niche. They have continued to expand their list of drugs and have the first FDA approved ADC. Dr. Siegall seeks to end the reign of the older cancer treatment options like the systemic chemotherapy.

In fact, the dire effects of chemotherapy was part of the inspiration that led Dr. Siegall to starting the company in the first place. He watched a family member go through cancer treatment with chemotherapy, which had brutal side effects of severe anemia which nearly led to the family member’s death. He saw that the only options available were chemotherapy and invasive surgeries and he realized he needed to change that.

Yet, he had been fascinated with diseases and the ability of technology and medicine to restore health since studying zoology at the University of Maryland. Later, he went on to gain his doctorate in genetics from George Washington University.

Dr. Siegall has a long career in the research field. Prior to starting Seattle Genetics, Dr. Siegall was the senior researcher at Bristol Myers Squibb Pharmaceutical Research Institute. He also worked with the National Cancer Institute and is currently on the Board of Directors for Alder BioPharmaceuticals.

Dr. Siegal has also published more than 70 papers and has 15 patents. As the leader in the capital-raising activites, Dr. Siegall was able to gain $675 million of financing for Seattle Genetics. They have developed a diverse array of drugs in the pipeline, with the mainstay of ADCETRIS which was FDA approved in 2011.

Leave a reply

Your email address will not be published.

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>